Advaxis, Inc. (ADXS) Chief Financial Officer Sara Bonstein, Unloaded $16,612 in Stock; Weitz Investment Management Has Lowered Liberty Global Plc (LBTYK) Stake By $4.49 Million

Weitz Investment Management Inc decreased Liberty Global Plc (LBTYK) stake by 2.78% reported in 2017Q3 SEC filing. Weitz Investment Management Inc sold 140,395 shares as Liberty Global Plc (LBTYK)’s stock declined 17.26%. The Weitz Investment Management Inc holds 4.91M shares with $160.66 million value, down from 5.05 million last quarter. Liberty Global Plc now has $33.90B valuation. The stock decreased 0.93% or $0.32 during the last trading session, reaching $33.94. About 899,946 shares traded. Liberty Global plc (NASDAQ:LBTYK) has declined 6.78% since January 4, 2017 and is downtrending. It has underperformed by 23.48% the S&P500.

Sara Bonstein, an insider of Advaxis Inc, currently Chief Financial Officer lately disclosed a trade with the SEC. As discovered in the electronic document, Sara Bonstein sold 5,224 shares of the Pinksheet-listed company, priced at $3.2 per share. $16,612 U.S Dollars was the trade’s value. The SEC document’s date was 03-01-2018. Currently, Sara Bonstein owns a total of 224,013 shares or 0.54% of the company’s total market cap.

Since September 22, 2017, it had 0 buys, and 2 selling transactions for $8.05 million activity. 600,000 shares were sold by ADAGE CAPITAL PARTNERS GP – L.L.C., worth $2.58M on Wednesday, October 11.

Investors sentiment decreased to 1.23 in 2017 Q3. Its down 0.40, from 1.63 in 2017Q2. It dived, as 12 investors sold Advaxis, Inc. shares while 18 reduced holdings. 17 funds opened positions while 20 raised stakes. 16.94 million shares or 12.95% less from 19.46 million shares in 2017Q2 were reported. New York-based Goldman Sachs Group Inc has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Advaxis, Inc. (NASDAQ:ADXS). Raymond James Service Advisors reported 11,069 shares. Jefferies Group Inc accumulated 0.01% or 330,170 shares. Aqr Mngmt Ltd Llc holds 43,928 shares. Orca Investment Mngmt Ltd Liability holds 0.04% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 10,000 shares. Deutsche National Bank Ag has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Zacks Inv Mngmt invested in 0% or 12,317 shares. Ameritas Inv Prtnrs Incorporated holds 3,095 shares. New York-based Tower Capital Ltd Liability Co (Trc) has invested 0.01% in Advaxis, Inc. (NASDAQ:ADXS). Adage Cap Gru Limited Liability Com holds 0.05% or 4.70 million shares in its portfolio. Morgan Stanley holds 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 149,141 shares. Sg Americas Secs Limited Company accumulated 18,464 shares. Dafna Capital Management Lc holds 0.64% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 247,000 shares. Blackrock reported 2.30M shares.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $133.25 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Among 4 analysts covering Advaxis (NASDAQ:ADXS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis has $40 highest and $1900 lowest target. $28’s average target is 766.87% above currents $3.23 stock price. Advaxis had 8 analyst reports since September 11, 2015 according to SRatingsIntel. As per Wednesday, December 27, the company rating was maintained by H.C. Wainwright. Cantor Fitzgerald maintained it with “Buy” rating and $1900 target in Wednesday, May 31 report. The company was initiated on Friday, September 11 by Guggenheim. Cantor Fitzgerald maintained Advaxis, Inc. (NASDAQ:ADXS) on Monday, June 12 with “Buy” rating. On Tuesday, September 22 the stock rating was initiated by Barclays Capital with “Overweight”. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, July 6. As per Wednesday, November 8, the company rating was maintained by H.C. Wainwright. As per Wednesday, June 14, the company rating was maintained by H.C. Wainwright.